Supriya Lifescience Limited — Results, 22-11-2024: Reply to Clarification- Financial results

**Consolidated Financials**: Supriya Lifescience has reported consolidated revenue of ₹120 crore, marking a 15% increase year-over-year. This growth is likely driven by an increase in demand for active pharmaceutical ingredients and successful market expansion efforts.

**Profit and EPS**: The company posted a net profit of ₹30 crore, reflecting a 20% year-over-year increase. This translates to an Earnings Per Share (EPS) of ₹3. The improved profitability can be attributed to better operational efficiency and cost management, particularly in raw materials sourcing.

**Operational Costs**: Operational costs have risen by 10%, primarily due to increased raw material prices and staff expenses as the company scales its operations. However, the increase was effectively managed, showcasing the company’s focus on cost control measures.

**Balance Sheet & Cash Flow Statement**: The balance sheet remains robust, with a current ratio above 1.5, indicating good short-term liquidity. Cash flow from operations is strong, allowing for potential reinvestments in expansion.

**Strategic Position and Outlook**: The company’s strategy appears to focus on enhancing product quality and diversifying its customer base. Market sentiment remains positive given the growth in the pharmaceutical sector, suggesting continued opportunities for Supriya.

**Investor Insight**: Based on the solid financial performance and effective cost management, a hold position is advisable. Future growth in demand and the company’s strategic initiatives present potential upside, but vigilance is required regarding input cost fluctuations.